Method Development and Validation of Darifenacin in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study

about

Method Development and Validation of Darifenacin in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study

Item

http://www.wikidata.org/entity/Q58691998

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2012

@uk

name

Method Development and Validat ...... ion to a Pharmacokinetic Study

@en

Method Development and Validat ...... ion to a Pharmacokinetic Study

@nl

type

Item

label

Method Development and Validat ...... ion to a Pharmacokinetic Study

@en

Method Development and Validat ...... ion to a Pharmacokinetic Study

@nl

prefLabel

Method Development and Validat ...... ion to a Pharmacokinetic Study

@en

Method Development and Validat ...... ion to a Pharmacokinetic Study

@nl

P1476

Method Development and Validat ...... ion to a Pharmacokinetic Study

@en

P2093

B. R. Challa

http://www.w3.org/2001/XMLSchema#string

Thejomoorthy Karavadi

http://www.w3.org/2001/XMLSchema#string

P2860

Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data

Development and validation of bioanalytical methods for Imidafenacin (KRP-197/ONO-8025) and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry.

The clinical pharmacokinetics of darifenacin.

Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice.

Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study.

Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.

In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment.

Identification and structural elucidation of two process impurities and stress degradants in darifenacin hydrobromide active pharmaceutical ingredient by LC-ESI/MS(n).

Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man.

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5402/2012/659257

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime